Last Updated: 16 Sep 2024
Executive Summary
Becton Dickinson and Company (BDX) is a leading medical technology company with a strong financial performance and a promising outlook. The company's shares have outperformed the broader market in recent years, and analysts remain bullish on its long-term prospects.
Company Overview
BDX is a global manufacturer and distributor of medical devices, instrument systems, and reagents. The company's products are used in a wide range of healthcare settings, including hospitals, clinics, and laboratories. BDX has a strong global presence, with operations in more than 190 countries.
Fundamental Analysis
BDX has a strong financial profile. The company's revenue has grown steadily in recent years, and its profitability has improved significantly. BDX's gross profit margin is 44.5%, and its operating margin is 15.1%. The company's net income margin is 7.1%.
BDX's financial leverage is relatively low. The company's debt-to-equity ratio is 0.44, and its interest coverage ratio is 10.3. BDX has a strong cash flow from operations, and its free cash flow is $2.2 billion.
Technical Analysis
BDX's stock price has been in a strong uptrend in recent years. The stock has broken out of a long-term resistance level at $230, and it is now trading near its 52-week high. The stock's relative strength index (RSI) is 65, which indicates that it is overbought. However, the stock's moving average convergence divergence (MACD) is positive, which indicates that the uptrend is still intact.
Short Term Outlook
In the short term, BDX's stock price is likely to continue to rise. The stock is trading above its key moving averages, and the technical indicators are positive. The company's strong financial performance is also likely to support the stock price.
Long Term Outlook
In the long term, BDX's stock price is likely to continue to perform well. The company is a leader in the medical technology industry, and it has a strong track record of innovation and growth. The company's products are essential to the healthcare system, and the demand for its products is likely to continue to grow in the years to come.
Analyst Recommendations
Analysts are bullish on BDX's long-term prospects. The consensus analyst rating for the stock is "buy". The average analyst target price for the stock is $273.43, which represents a potential upside of 16.8% from the current price.
